Vir Biotechnology (VIR) FY2021 results: revenue $1.1 billion, up 1334.4% on the year
Vir Biotechnology, Inc. (VIR) reported revenue of $1.1 billion for fiscal 2021, the year ended 31 December 2021, up 1334.4% on the year before. Net income was $529 million, and diluted earnings per share $3.96. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2022.
Revenue
$1.1 billion
+1,334.4% on the year
FY2017FY2021
Operating margin
38.4%
-388.9% a year earlier
FY2017FY2021
Net income
$529 million
FY2017FY2021
Diluted EPS
$3.96
FY2017FY2021
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Operating cash flow
-47.6
-191
-130
Capital expenditure
21.8
6.5
8.9
+233.1%
Free cash flow
-69.4
-197
-139
Free cash flow margin
-6.3%
-258.6%
-1712.7%
Cash from investing
-141
-9.9
-256
Cash from financing
100
529
449
-81.1%
Depreciation and amortisation
5.3
4.4
3.3
+20.0%
Share-based compensation
83.8
27.6
8.7
+203.6%
Diluted shares, weighted
133m
119m
30m
+12.0%
Shares outstanding at period end
131m
127m
108m
+2.9%
Balance sheet
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Shareholders' equity
1,432
717
424
+99.7%
Debt
0.0
0.0
n/a
Operating lease liabilities
134
66.6
n/a
+100.7%
Finance lease liabilities
n/a
0.7
0.9
Other liabilities
389
135
87.2
+188.8%
Total liabilities and equity
1,954
919
512
+112.7%
Fixed assets
42.8
17.9
16.3
+138.7%
Goodwill
16.9
16.9
16.9
0.0%
Intangible assets
33.3
33.8
35.7
-1.6%
Investments
419
300
298
+39.4%
Cash and equivalents
348
437
109
-20.3%
Receivables
773
0.0
n/a
Other assets
322
113
35.4
+184.2%
Total assets
1,954
919
512
+112.7%
10-K for the year ended 31 December 2021, filed 28 February 2022: the filing.